

4th July, 2022

Jia-Ping Yan
Science Editor Office
World Journal of Clinical Oncology

Dear Jia-Ping Yan and reviewers of the manuscript,

First of all, we want to thank you for your kind comments about our **letter to the editor** about the neoadjuvant immunotherapy in NSCLC and for the acceptance to be published in **World Journal of Clinical Oncology**.

Please find enclosed our last version of the manuscript entitled **“Neoadjuvant immunotherapy in non-small-cell lung cancer: times are changing—and fast”** which we submit for consideration as an **unsolicited** article. This is a letter to the editor to add key new information about neoadjuvant chemo-immunotherapy combo in neoadjuvant setting of NSCLC, because this information was not available when we wrote our article 67611.

We have disclosed our conflicts of interests in the COI form. We confirm that this work is original and has not been published previously, nor is it currently under consideration for publication elsewhere. We confirm that the manuscript has been read and approved for submission by all the named authors.

Yours sincerely,

Carlos Aguado,

Corresponding Author

Carlos Aguado, MD. Department of Medical Oncology, Hospital Universitario
Clínico San Carlos, Madrid 28040, Spain
carlos.aguado84@gmail.com